All You Need to Know About Cardinal (CAH) Rating Upgrade to Buy

Cardinal Health (CAH) has been upgraded to a Zacks Rank #2 (Buy), reflecting a 4.6% increase in its Zacks Consensus Earnings Estimate over the past three months. This upgrade, driven by an improving earnings outlook with a fiscal year 2026 EPS estimate of $9.37, positions CAH in the top 20% of Zacks-covered stocks. The Zacks Rank system correlates such positive earnings estimate revisions with potential near-term stock appreciation, indicating a favorable impact on CAH's stock price.

Analysis

Cardinal Health (CAH) has been upgraded to a Zacks Rank #2 (Buy), a move predicated on a positive trend in its earnings estimate revisions. Specifically, the Zacks Consensus Estimate for the company has risen 4.6% over the past three months, signaling strengthening analyst sentiment on its near-term business fundamentals. The upgrade places CAH in the top 20% of stocks covered by the rating system, which historically correlates with potential for near-term price appreciation driven by institutional buying. However, while estimates have been revised upward, the forecast for the fiscal year ending June 2026 stands at $9.37 per share, a figure which the report notes represents no year-over-year change. This suggests that while the near-term outlook has improved, the longer-term earnings growth profile for that specific period is currently perceived as flat.

Key Decisions for Investors

• The upgrade to a Zacks Rank #2, driven by a 4.6% increase in consensus estimates, presents a bullish signal for near-term momentum and should be considered by investors who prioritize earnings revisions in their models.
• Investors should scrutinize the company's forward growth trajectory, as the fiscal 2026 EPS estimate of $9.37 currently implies a flat year-over-year earnings profile, which may temper long-term expectations.
• Given the stock's placement in the top quintile for earnings revisions, it could be a candidate for tactical overweighting relative to peers, but this should be weighed against the lack of projected growth in the FY2026 forecast.